ACORN: Skeletal Effects of Chronic Night Shift

Sponsor
University of Colorado, Denver (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05091021
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (NIH)
40
1
50.2
0.8

Study Details

Study Description

Brief Summary

The specific aim of this observational study is to characterize changes in bone turnover makers (BTMs), bone mineral density (BMD), and bone microarchitecture in a cohort of nurses during their first year of night compared to day shift work. The hypothesis is that night shift nurses will have poorer bone health indices at one year compared to day shift nurses.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    40 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Skeletal Effects of Chronic Night Shift (ACORN Study)
    Actual Study Start Date :
    Oct 27, 2021
    Anticipated Primary Completion Date :
    Jan 1, 2026
    Anticipated Study Completion Date :
    Jan 1, 2026

    Arms and Interventions

    Arm Intervention/Treatment
    University of Colorado Health New Nurses (Day Shift Workers)

    University of Colorado Health New Nurses (Night Shift Workers)

    Outcome Measures

    Primary Outcome Measures

    1. Difference in change of propeptide of type 1 procollagen (P1NP) over 1 year [From baseline up to 12 months]

      Difference in change of P1NP over 1 year between the two groups (night vs. day shift nurses), as measured via bone biomarker assays (immunodiagnostic systems, chemiluminescence, immunoassay)

    Secondary Outcome Measures

    1. Between-group differences in the change in osteocalcin [From baseline up to 12 months]

      Between-group differences in the change in another bone formation marker (osteocalcin)

    2. DXA-derived areal bone mineral density (aBMD) changes [From baseline up to 12 months]

      Between-group differences in aBMD at the lumber spine, total hip and femoral neck measured by DXA

    3. Change in bone microarchitecture [From baseline up to 12 months]

      Change in trabecular volumetric BMD (vBMD) derived from high-resolution peripheral quantitative computed tomography (HR-pQCT)

    4. Between-group differences in the change in CTX (C-telopeptide of type I collagen) [From baseline up to 12 months]

      Between-group differences in the change in a bone resorption marker (CTX)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 50 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes

    Inclusion Criteria

    • Healthy, nonpregnant adults 20-50 years old who recently (≤6 months) graduated from nursing school and were hired by University of Colorado Hospital for their first nursing position

    • For women to be eligible, they must be premenopausal, not breastfeeding, not pregnant with no plans to become pregnant during the year of observation and willing/able to maintain their current method of contraception use as detailed below.

    • Willing and able to travel to/from CU-AMC for study measurements at baseline and quarterly for one full year Exclusion Criteria

    • Non-nursing school related shift work 1 year prior to study.

    • Current smokers at baseline (or within the previous year of study).

    • Individuals who are concurrently participating in another research protocol that would influence their safe participation in this study. For example, participants involved in a study that requires blood draws or ingestion of experimental medication as this would increase the risk of participation in our study and/or compromise study results.

    • Any clinically significant unstable medical or surgical condition within the last year (treated or untreated), including history of a clinically significant abnormality of the neurological system (including cognitive disorders or significant head injury) or any history of seizure (including febrile seizure-sleep loss has been used clinically to induce seizures in patients with epilepsy). Given the wide range of illnesses that are encountered in medical practice, it would not be possible to provide a comprehensive list of each and every disease that could serve as grounds for exclusion for the subject. However, the following is a list of illness categories that would certainly be grounds for exclusion: Connective Tissue and Joint Disorders; Neurologic/cognitive Disorders; Musculoskeletal Disorders; Immune Disorders; Chronobiologic Disorders; Cardiovascular Disorders; Respiratory Disorders; Kidney Disorders; Infectious Diseases; Hematopoietic Disorders; Neoplastic Diseases; and Endocrine and Metabolic Diseases.

    • Self-reported or newly diagnosed medical condition that is still being investigated or is not under good control, including those identified on screening labs such as:

    o Out-of-range values measured on a fasting blood sample: glucose > 100 mg/dl, thyroid stimulating hormone <0.5 or >5.0 uU/ml, abnormal alkaline phosphatase <39 or >117 U/l, creatinine, or hemoglobin <14.5 g/dl men

    • Any clinically significant psychiatric condition, as defined by DSM-V. Individuals with a history of most psychiatric illnesses or psychiatric disorders will be excluded, such as but not limited to depression, anxiety, alcoholism, drug dependency, schizophrenic disorders, and personality disorders (performed by medical history and physician interview). However, a personal history of limited prior counseling, psychotherapy (e.g., for adjustment reactions) will NOT be exclusionary.

    • Evaluation of Psychiatric/Psychological Suitability:

    • Inability to demonstrate a full understanding of the requirements and demands of the study.

    • Individuals who are unaware of specific psychiatric diagnoses who have a history of having been treated with antidepressants, neuroleptic medications or major tranquilizers will be excluded from study.

    • Use of anti-depressants or any like therapeutics prescribed by a physician is exclusionary

    • Individuals with any clinically significant sleep disorder; Diagnosis or symptoms of sleep disorders (history of significant parasomnia as an adult [night terrors, frequent sleep walking], insomnia, including but not limited to hypersomnias such as apnea, periodic limb movements, narcolepsy). Sleep disorders will be screened by self-report and physician interview including use of validated sleep questionnaires (PSQI, Epworth sleepiness scale, and Berlin sleep questionnaire for sleep apnea).

    • Individuals on medications known to affect bone turnover (e.g., glucocorticoids, osteoporosis medications);

    • Individuals with eGFR < 60 mL/min/1.73m2 as this is known to affect CTX measurements.

    • Symptoms of active illness (e.g., fever) at time of enrollment; note - participant may be studied at a later date if they have not yet started their clinical duties by that time

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 CU Anschutz Aurora Colorado United States 80045

    Sponsors and Collaborators

    • University of Colorado, Denver
    • National Heart, Lung, and Blood Institute (NHLBI)

    Investigators

    • Principal Investigator: Christine M Swanson, MD, MCR, CU Anschutz

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Colorado, Denver
    ClinicalTrials.gov Identifier:
    NCT05091021
    Other Study ID Numbers:
    • 20-3014
    • R01HL151332
    First Posted:
    Oct 25, 2021
    Last Update Posted:
    Jun 24, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 24, 2022